{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:27:49Z","timestamp":1770996469050,"version":"3.50.1"},"reference-count":33,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-\u03b1, with\/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon \u03b1-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon \u03b1-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon \u03b1-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor\u2013naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon \u03b1-2b in patients with previously treated checkpoint inhibitor\u2013naive RCC and of atezolizumab plus PEG-interferon \u03b1-2a and bevacizumab in patients with treatment-naive RCC.<\/jats:p>","DOI":"10.3390\/curroncol28060455","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:23:47Z","timestamp":1640060627000},"page":"5466-5479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase Ib Study of Atezolizumab Plus Interferon-\u03b1 with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors"],"prefix":"10.3390","volume":"28","author":[{"given":"Christian U.","family":"Blank","sequence":"first","affiliation":[{"name":"Netherlands Cancer Institute-Antoni van Leeuwenhoek, 1066 Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah J.","family":"Wong","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0023-2939","authenticated-orcid":false,"given":"Thai H.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd M.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute\/Tennessee Oncology, PLLC, Nashville, TN 37203, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie B.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Bene-Tchaleu","sequence":"additional","affiliation":[{"name":"Hoffmann-La Roche Ltd., Mississauga, ON L5N 5M8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Cha","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA 94080, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, Yale School of Medicine, New Haven, CT 06520, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0959-8049(05)80164-9","article-title":"Advances in systemic treatment of malignant melanoma","volume":"29","author":"Aapro","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.kint.2020.08.028","article-title":"Immune evasion in renal cell carcinoma: Biology, clinical translation, future directions","volume":"99","author":"Wang","year":"2021","journal-title":"Kidney Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Rizzo, A., Mollica, V., Santoni, M., Ricci, A.D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., and Massari, F. (2021). Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials. Eur. Urol. Focus.","DOI":"10.1016\/j.euf.2021.03.001"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-based combinations for the treatment of metastatic renal cell carcinoma: A meta-analysis of randomised clinical trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.5306\/wjco.v11.i8.541","article-title":"Combination drug regimens for metastatic clear cell renal cell carcinoma","volume":"11","author":"Khetani","year":"2020","journal-title":"World J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Aric\u00f2, E., Castiello, L., Capone, I., Gabriele, L., and Belardelli, F. (2019). Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications. Cancers, 11.","DOI":"10.3390\/cancers11121943"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","article-title":"Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors","volume":"101","author":"Seliger","year":"2008","journal-title":"Adv. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.4049\/jimmunol.1003208","article-title":"IFN-\u03b1 Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity","volume":"186","author":"Terawaki","year":"2011","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1200\/JCO.18.00632","article-title":"Phase Ib\/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma","volume":"36","author":"Davar","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","article-title":"Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF","volume":"110","author":"Huang","year":"2007","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4049\/jimmunol.1502638","article-title":"Chronic Type I IFN Is Sufficient To Promote Immunosuppression through Accumulation of Myeloid-Derived Suppressor Cells","volume":"198","author":"Taleb","year":"2016","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1128\/MCB.00224-09","article-title":"Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18\/UBP43","volume":"29","author":"Wang","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon Alfa-2a in Patients with Chronic Hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an Anti\u2013Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study","volume":"34","author":"McDermott","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol. Cancer Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:50:07Z","timestamp":1760169007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060455"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060455","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]}}}